Apellis Pharmaceuticals, Inc. (APLS): Price and Financial Metrics
GET POWR RATINGS... FREE!
APLS POWR Grades
- Quality is the dimension where APLS ranks best; there it ranks ahead of 46.48% of US stocks.
- APLS's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- APLS's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).
APLS Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for APLS is 4.85 -- better than 92.5% of US stocks.
- With a year-over-year growth in debt of 158.34%, Apellis Pharmaceuticals Inc's debt growth rate surpasses 93.51% of about US stocks.
- As for revenue growth, note that APLS's revenue has grown 38,699.69% over the past 12 months; that beats the revenue growth of 99.95% of US companies in our set.
- Stocks that are quantitatively similar to APLS, based on their financial statements, market capitalization, and price volatility, are RGLS, AUPH, RVNC, OCX, and SAGE.
- Visit APLS's SEC page to see the company's official filings. To visit the company's web site, go to www.apellis.com.
APLS Price Target
For more insight on analysts targets of APLS, see our APLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $72.29 | Average Broker Recommendation | 1.38 (Strong Buy) |
APLS Stock Price Chart Interactive Chart >
APLS Price/Volume Stats
| Current price | $62.12 | 52-week high | $62.16 |
| Prev. close | $60.91 | 52-week low | $25.49 |
| Day low | $58.82 | Volume | 467,800 |
| Day high | $62.16 | Avg. volume | 713,871 |
| 50-day MA | $48.78 | Dividend yield | N/A |
| 200-day MA | $43.92 | Market Cap | 5.00B |
Apellis Pharmaceuticals, Inc. (APLS) Company Bio
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company was founded in 2009 and is based in Crestwood, Kentucky.
Latest APLS News From Around the Web
Below are the latest news stories about Apellis Pharmaceuticals Inc that investors may wish to consider to help them evaluate APLS as an investment opportunity.
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsNEW YORK, NY / ACCESSWIRE / June 9, 2021 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Apellis Pharmaceuticals, Inc.If you are a shareholder of Apellis Pharmaceuticals, Inc. |
Apellis Pharmaceuticals to Present at Upcoming Investor ConferencesWALTHAM, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will participate in the following investor conferences in June: Goldman Sachs Healthcare Conference: Fireside chat on Thursday, June 10, 2021 at 8:00 a.m. ET.Bank of America Napa Biopharma Conference: Fireside chat on Wednesday, June 16, 2021 at 4:30 p.m. ET. The Conference events will be available |
Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH StudyApellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients. |
Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder StudyApellis Pharmaceuticals Inc (NASDAQ: APLS) and Swedish Orphan Biovitrum AB (SOBI) have reported positive top-line results from the Phase 3 PRINCE study evaluating Empaveli (pegcetacoplan) in treatment naïve paroxysmal nocturnal hemoglobinuria (PNH) patients. Empaveli demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization and reduction in lactate dehydrogenase (LDH) compared to standard of care, which did not include complement inhibitors, at Week 26. 86% of Empaveli-treated patients achieved hemoglobin stabilization compared to 0% of patients on standard of care. Mean LDH in the Empaveli group decreased by 90% from a baseline, compared to 14%. Mean hemoglobin levels in the Empaveli group increased from 9.4 g/dL to 12.1 g/dL compared to an increase f... |
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNHEMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which did not include complement inhibitors, at Week 26 Mean hemoglobin levels in the EMPAVELI group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019)91% of patients on EMPAVELI were transfusion free compared to 22% on standard of care (p<0.0001)The safety profile of EMPAVELI was consistent with previous studies WALTHAM, Mass. and STOCKHOLM, Sweden, May 25, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today reported positive top-line results f... |
APLS Price Returns
| 1-mo | 36.11% |
| 3-mo | 33.13% |
| 6-mo | 19.35% |
| 1-year | 100.52% |
| 3-year | 182.43% |
| 5-year | N/A |
| YTD | 8.60% |
| 2020 | 86.81% |
| 2019 | 132.15% |
| 2018 | -39.22% |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...